BioSpace News Archive

Endologix LLC , a privately held global medical device company dedicated to improving patients’ lives by providing disruptive therapies for the interventional treatment of vascular disease, announced the 12-month results of the DETOUR 2 trial during a late-breaking clinical trial session at the 2022 VIVA Vascular InterVentional Advances (VIVA) Conference in Las Vegas, Nevada.

PAVmed Inc. today announced that Lishan Aklog, M.D. , PAVmed’s Chairman and CEO, will participate in the Technologies Ushering in Next-Generation Diagnostics, Therapies, and Surgeries virtual panel discussion on November 21, 2022 from 12:00 pm to 12:55 pm EST.

Biomea Fusion, Inc. today announced that Biomea’s management will participate in a fireside chat and host investor meetings at the upcoming Piper Sandler 34th Annual Healthcare Conference.

Surmodics, Inc. announced today that Professor Ramon Varcoe will present 12-month data from the SWING Trial, a first-in-human study of the safety and efficacy of the Sundance™ Sirolimus Drug-Coated Balloon (DCB).

Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, announced highlights from three Phase 3 clinical trials, OA-07, OA-10 and OA-11 for its knee OA drug candidate, lorecivivint.

Mymee, Inc. announced the completion of a multi-year retrospective study designed to assess the program’s impact on health-related quality of life (HRQoL) and the use of personal data to identify unique sensitivities to hidden triggers within their food and environment.

RemeGen Co., Ltd., a leading biopharmaceutical company with fully integrated capabilities in research and discovery, clinical development, manufacturing, and commercialization of biologic drugs, will join the event of the American College of Rheumatology (ACR) 2022, hosted from November 10th to 14th.

Nemaura Medical, Inc. announces today that CEO Dr. Faz Chowdhury will present a corporate overview at at the Bernstein 2nd Annual CGM Disruptors Conference which is being held virtually on November 18, 2022.

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today its participation in two November conferences, the Challenges and Opportunities for Mesenchymal Stem Cells digital conference being held November 17-18, 2022 and A.G.P.’s Biotech Conference on November 30, 2022.

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Responders, today announced preclinical data on immuno-oncology candidates OR2805 and OR502 presented at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.